search
Back to results

Dynamic Connectivity Under Metabolic Constraints

Primary Purpose

Insulin Resistance, Healthy, Diet Modification

Status
Unknown status
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Ketones
Glucose
Sponsored by
Stony Brook University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Insulin Resistance focused on measuring insulin resistance, exogenous ketone, glucose, diet, aging

Eligibility Criteria

18 Years - 79 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Exclusion Criteria:

  • claustrophobia
  • history of neurological disease, heart attack, stroke, kidney disease, or myxedema
  • chronic usage of alcohol
  • current usage of psychotropic medication
  • Type 1 diabetes mellitus
  • Regular consumption of insulin, Metformin® or other medications (statins, NSAIDs, beta-blockers, glucocorticoids) that affect glucose and/or insulin utilization.
  • difficulty swallowing
  • pregnancy
  • breastfeeding
  • For PET: research imaging-related radiation exposure that exceeds current MGH Radiology Radiation Safety Commitee guidelines.

Inclusion Criteria:

  • BMI < 30
  • MRI compatible
  • For PET with Optional 150 ml Blood Sampling Only: Must weigh at least 110 lbs to minimize risks per PHRC guidelines.
  • 20/20 vision or correctable to 20/20 with contact lenses

Sites / Locations

  • Martinos Center for Biomedical Research, Building 149Recruiting
  • Bioengineering Building , Stony Brook UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Arm 1: Metabolic Manipulation via Diet fMRI

Arm 2: Metabolic Manipulation via Ketone Supplement fMRI

Arm 3: Metabolic Manipulation via Ketone Supplement MR/PET

Arm Description

All subjects are tested three times, each in a different diet-induced metabolic state: glycolytic (glucose burning), fasting (8 hours no food), and ketotic (fat burning). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink up to 75g glucose. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).

All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink either of two fuel sources. In the ketotic (ketone burning) session they will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).

All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). For both sessions, the investigators will intravenously administer the FDG radioisotope continuously throughout the scan. Thus, PET will map glucose uptake across the brain, while MRS is simultaneously used to measure production of the neurotransmitters glutamine and GABA. While having their brains scanned with MR/PET, subjects are initially tested at rest, and then perform a task. Subjects will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones.

Outcomes

Primary Outcome Measures

Diet related changes in brain network stability will be assessed by fMRI BOLD measurements.
Changes in BOLD signal measurements will be observed between baseline and during a glycolytic, fasting, or ketotic state.
Glucose uptake will be measured by PET, with and without ketone supplement
Continuous FDG PET infusion is used as a measure of glucose uptake during rest and task, with and without the ketone supplement.
Neurotransmitter production with and without ketone supplement will be measured by magnetic resonance spectroscopy
Changes in neurotransmitter concentration under metabolic demands (i.e., task vs resting-state) with and without ketone supplement will be assessed by magnetic resonance spectroscopy.

Secondary Outcome Measures

Cognitive performance will be assessed by Mini Mental State Exam (MMSE).
All subjects will undergo cognitive testing prior to MRI scanning using the MMSE exam.
Cognitive performance will be assessed by CNS Vital Signs.
All subjects will undergo cognitive testing prior to MRI scanning using the CNS Vital Signs exam.
Insulin resistance will be assessed by HbA1C.
All subjects will be tested for insulin resistance prior to MRI scanning using veinous blood collected and tested for HbA1C.
Insulin resistance will be assessed by blood insulin level.
All subjects will be tested for insulin resistance prior to MRI scanning using veinous blood collected and tested for insulin during a 2-hour Oral Glucose Tolerance Test (OGTT).
Insulin resistance will be assessed by blood glucose level.
All subjects will be tested for insulin resistance prior to MRI scanning using veinous blood collected and tested for glucose during a 2-hour Oral Glucose Tolerance Test (OGTT).

Full Information

First Posted
September 17, 2019
Last Updated
September 25, 2019
Sponsor
Stony Brook University
Collaborators
Martinos Center for Biomedical Imaging
search

1. Study Identification

Unique Protocol Identification Number
NCT04106882
Brief Title
Dynamic Connectivity Under Metabolic Constraints
Official Title
Dynamic Connectivity Under Metabolic Constraints
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Unknown status
Study Start Date
June 19, 2015 (Actual)
Primary Completion Date
September 2022 (Anticipated)
Study Completion Date
September 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Stony Brook University
Collaborators
Martinos Center for Biomedical Imaging

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators are studying the impact of insulin resistance on the acceleration of brain aging and testing whether increased neuron insulin resistance can be counteracted by utilization of alternate metabolic pathways (e.g., ketones rather than glucose). This study has three Arms, which together provide synergistic data. For all three Arms, subjects are tested in a within-subjects design that consists of 2-3 testing sessions, 1-14 days apart, and counter-balanced for order. Impact of fuel (glucose in one session, ketones in the other) on brain metabolism and associated functioning is measured during each session. For Arms 1-2, the primary experimental measure is functional magnetic resonance imaging (fMRI), which is used to trace the self-organization of functional networks following changes in energy supply and demand. Arm 1 tests the impact of endogenous ketones produced by switching to a low carbohydrate diet, while Arm 2 tests the impact of exogenous ketones consumed as a nutritional supplement. For Arm 3, simultaneous magnetic resonance spectroscopy/positron-emission tomography (MR/PET) is used to quantify the impact of exogenous ketones on production of glutamate and GABA, key neurotransmitters. Subjects will be given the option to participate in more than one of the Arms, but doing so is not expected nor required. Prior to scans, subjects will receive a clinician-administered History and Physical (H&P), which includes vital signs, an oral glucose tolerance test (OGTT), and the comprehensive metabolic blood panel. These will be used to assess diabetes, kidney disease, and electrolytes. If subjects pass screening, they will be provided the option to participate in one or more Arms, which include neuroimaging. To provide a quantitative measure of time-varying metabolic activity throughout the scan, based upon quantitative models of glucose and ketone regulation, as well as to be able to implement safety stopping rules (see below), the investigators will obtain pin-prick blood samples three times: prior to the scan, following consumption of the glucose or ketone drink, and following completion of the scan. To assess effects of increased metabolic demand, the investigators measure brain response to cognitive load, transitioning from resting-state to spatial reasoning through a spatial navigation video task. To assess effects of increased metabolic supply, the investigators measure brain response to glucose or ketone bolus.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insulin Resistance, Healthy, Diet Modification, Aging
Keywords
insulin resistance, exogenous ketone, glucose, diet, aging

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm 1: Metabolic Manipulation via Diet fMRI
Arm Type
Experimental
Arm Description
All subjects are tested three times, each in a different diet-induced metabolic state: glycolytic (glucose burning), fasting (8 hours no food), and ketotic (fat burning). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink up to 75g glucose. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
Arm Title
Arm 2: Metabolic Manipulation via Ketone Supplement fMRI
Arm Type
Experimental
Arm Description
All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink either of two fuel sources. In the ketotic (ketone burning) session they will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
Arm Title
Arm 3: Metabolic Manipulation via Ketone Supplement MR/PET
Arm Type
Experimental
Arm Description
All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). For both sessions, the investigators will intravenously administer the FDG radioisotope continuously throughout the scan. Thus, PET will map glucose uptake across the brain, while MRS is simultaneously used to measure production of the neurotransmitters glutamine and GABA. While having their brains scanned with MR/PET, subjects are initially tested at rest, and then perform a task. Subjects will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones.
Intervention Type
Drug
Intervention Name(s)
Ketones
Intervention Description
Supplement administered mid-scan.
Intervention Type
Drug
Intervention Name(s)
Glucose
Intervention Description
Supplement administered mid-scan.
Primary Outcome Measure Information:
Title
Diet related changes in brain network stability will be assessed by fMRI BOLD measurements.
Description
Changes in BOLD signal measurements will be observed between baseline and during a glycolytic, fasting, or ketotic state.
Time Frame
Within two weeks of enrollment completion
Title
Glucose uptake will be measured by PET, with and without ketone supplement
Description
Continuous FDG PET infusion is used as a measure of glucose uptake during rest and task, with and without the ketone supplement.
Time Frame
Within two weeks of enrollment completion
Title
Neurotransmitter production with and without ketone supplement will be measured by magnetic resonance spectroscopy
Description
Changes in neurotransmitter concentration under metabolic demands (i.e., task vs resting-state) with and without ketone supplement will be assessed by magnetic resonance spectroscopy.
Time Frame
Within two weeks of enrollment completion
Secondary Outcome Measure Information:
Title
Cognitive performance will be assessed by Mini Mental State Exam (MMSE).
Description
All subjects will undergo cognitive testing prior to MRI scanning using the MMSE exam.
Time Frame
Within two weeks of enrollment completion
Title
Cognitive performance will be assessed by CNS Vital Signs.
Description
All subjects will undergo cognitive testing prior to MRI scanning using the CNS Vital Signs exam.
Time Frame
Within two weeks of enrollment completion
Title
Insulin resistance will be assessed by HbA1C.
Description
All subjects will be tested for insulin resistance prior to MRI scanning using veinous blood collected and tested for HbA1C.
Time Frame
Within two weeks of enrollment completion
Title
Insulin resistance will be assessed by blood insulin level.
Description
All subjects will be tested for insulin resistance prior to MRI scanning using veinous blood collected and tested for insulin during a 2-hour Oral Glucose Tolerance Test (OGTT).
Time Frame
Within two weeks of enrollment completion
Title
Insulin resistance will be assessed by blood glucose level.
Description
All subjects will be tested for insulin resistance prior to MRI scanning using veinous blood collected and tested for glucose during a 2-hour Oral Glucose Tolerance Test (OGTT).
Time Frame
Within two weeks of enrollment completion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Exclusion Criteria: claustrophobia history of neurological disease, heart attack, stroke, kidney disease, or myxedema chronic usage of alcohol current usage of psychotropic medication Type 1 diabetes mellitus Regular consumption of insulin, Metformin® or other medications (statins, NSAIDs, beta-blockers, glucocorticoids) that affect glucose and/or insulin utilization. difficulty swallowing pregnancy breastfeeding For PET: research imaging-related radiation exposure that exceeds current MGH Radiology Radiation Safety Commitee guidelines. Inclusion Criteria: BMI < 30 MRI compatible For PET with Optional 150 ml Blood Sampling Only: Must weigh at least 110 lbs to minimize risks per PHRC guidelines. 20/20 vision or correctable to 20/20 with contact lenses
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lilianne Mujica-Parodi, PhD
Phone
631-371-4413
Email
lilianne.strey@stonybrook.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Liam McMahon, BA
Email
liam.mcmahon@stonybrook.edu
Facility Information:
Facility Name
Martinos Center for Biomedical Research, Building 149
City
Charlestown
State/Province
Massachusetts
ZIP/Postal Code
02129
Country
United States
Individual Site Status
Recruiting
Facility Name
Bioengineering Building , Stony Brook University
City
Stony Brook
State/Province
New York
ZIP/Postal Code
11794
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lilianne Mujica-Parodi, PhD

12. IPD Sharing Statement

Learn more about this trial

Dynamic Connectivity Under Metabolic Constraints

We'll reach out to this number within 24 hrs